Barrett esophagus

Current Opinion in Gastroenterology

Volumn 19, Issue 4, 2003, Pages 387-393

  Slehria, Sanjeev ^a   Sharma, Prateek ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Dysplasia; Intestinal metaplasia; Screening; Short segment Barrett esophagus; Surveillance

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; METHYLENE BLUE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROTEIN P53; PROTON PUMP INHIBITOR; PROTOPORPHYRIN; ROFECOXIB; SULINDAC;

ADENOCARCINOMA; ALCOHOL CONSUMPTION; ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RISK; CANCER SCREENING; DYSPLASIA; ENDOSCOPIC THERAPY; ENDOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FLUORESCENCE; GASTROESOPHAGEAL REFLUX; GENE MUTATION; HEALTH CARE COST; HETEROZYGOSITY LOSS; HIATUS HERNIA; HUMAN; METAPLASIA; MORBIDITY; MORTALITY; PATHOGENESIS; PHOTODYNAMIC THERAPY; REVIEW; RISK FACTOR; SMOKING; STOMACH FUNDOPLICATION;

EID: 0037662082     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200307000-00011     Document Type: Review

References (35)

1. Sharma P, Morales TG, Sampliner RE: Short segment Barrett's segment: the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 1998, 93:1033-1036.
2. Pera M, Cameron AJ, Trastek VF, et al.: Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993, 104:510-513.
3. Devesa SS, Blot WJ, Fraumeni JF: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1988, 83:2049-2053.
4. Shaheen NJ, Crosby MA, Bozymski EM, et al.: Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000, 119:333-338.
5. Avidan B, Sonnenberg A, Schnell TG, et al.: Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig Dis Sci 2002, 47:256-264.
6. Caygill C, Johnston D, Lopez M, et al.: Lifestyle factors and Barrett's esophagus. Am J Gastroenterol 2002, 97:1328-1331.
7. Chak A, Lee T, Kinnard MF, et al.: Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002, 51:323-328.
8. Avidan B, Sonnenberg A, Schnell T, et al.: Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002, 97:1930-1936. The Study characterized risk factors for the transition from Barrett's esophagus without dysplasia to Barrett's esophagus with high grade dysplasia or adenocarcinoma.
9. Fitzgerald RC, Abdalla S, Onwuegbusi BA, et al.: Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002, 51:316-322.
10. Eloubeidi MA, Provenzale D: Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy. Am J Gastroenterol 1999, 94:937-943.
11. Jones T, Sharma P, Weston A, et al.: Yield of intestinal metaplasia in patients with suspected short segment Barrett's esophagus (SSBE) on repeat endoscopy. Dig Dis Sci 2002, 47:2108-2111.
12. Csendes A, Smok G, Quiroz J, et al.: Clinical, endoscopic, and functional studies in 408 patients with Barrett's esophagus, compared to 174 cases of intestinal metaplasia of the cardia. Am J Gastroenterol 2002, 97:554-560.
13. Zentilin P, Conio M, Mele MR, et al.: Comparison of the main oesophageal pathophysiological characteristics between short- and long-segment Barrett's oesophagus. Aliment Pharmacol Ther 2002, 16:8893-8898.
14. Theisen J, Stein HJ, Dittler HJ, et al.: Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc 2002, 16:671-673. Segments of intestinal metaplasia can be masked by overgrowth of esophageal adenocarcinoma. Chemotherapy unmasked underlying Barrett's esophagus in the majority of patients with no previous history of Barrett's.
15. Corley DA, Levin TR, Habel LA, et al.: Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002, 122:633-640. A population based study showing the outcome of surveillance in patients with Barrett's esophagus on esophageal adenocarcinoma development (stage and survival).
16. Dulai GS, Guha S, Kahn KL, et al.: Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002, 122:26-33.
17. Fisher D, Jefferys A, Stat M, et al.: Quality of life in patients with Barrett's esophagus undergoing surveillance. Am J Gastroenterol 2002, 97:2193-2200.
18. Saeian K, Staff D, Vasilopoulos S, et al.: Unsedated transnasal endoscopy accurately detects Barrett's metaplasia and dysplasia. Gastrointest Endosc 2002, 56:472-478. Unsedated trans nasal upper endoscopy is accurate and cost effective for confirmation of Barrett's metaplasia with yield for dysplasia comparable with conventional upper endoscopy.
19. Sharma P, Topalovski M, Weston A, et al.: Methylene blue chromoendoscopy for detection of short segment Barrett's esophagus. Gastrointest Endosc 2001, 54:289-293. Using vital staining techniques increase the yield for detection of intestinal metaplasia. Chromoendoscopy with methylene blue significantly increased the detection of intestinal metaplasia in patients with suspected SSBE.
20. Brand S, Wang D, Schomacker K, et al.: Detection of high grade dysplasia in Barrett's esophagus by spectroscopy measurement of 5-aminolevulinic acid-induced protoporphyrin IX fluorescence. Gastrointest Endosc 2002, 56:479-487.
21. Reid BJ, Prevo LJ, Galipeau PC, et al.: Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001, 96:2839-2848. Panel of biomarkers can be used to assess risk of progression in Barrett's to high-grade dysplasia and adenocarcinoma. p16 loss of heterozygosity successfully predicted those patients at high risk for progression to esophageal adenocarcinoma.
22. Bian YS, Osterheld MC, Fontolliet C, et al.: p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 2002, 122:1113-1121.
23. Xu Y, Selaru FM, Yin J, et al.: Artificial neural networks and gene filtering distinguish between global gene expression profiles of Barrett's esophagus and esophageal cancer. Cancer Res 2002, 62:3493-3497.
24. Basu KK, Bale R, West KP, et al.: Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy. Eur J Gastroenterol Hepatol 2002, 14:1187-1192.
25. Carlson N, Richter J, Sampliner R, et al. Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. Am J Gastroenterol 2002, 97:1340-1345.
26. Souza RF, Shewmake K, Terada LS, et al.: Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002, 122:299-307.
27. Buttar N, Wang K, Leontovich O, et al.: Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002;122:1101-1112. An important animal study showing that COX-@ inhibitors can inhibit inflammation and development of adenocarcinoma in a rat model.
28. Kaur BS, Khamnehel N, Triadafilopoulos G, et al.: Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002, 23:60-67.
29. Csendes A, Burdiles P, Braghetto I, et al.: Dysplasia and adenocarcinoma after classic antireflux surgery in patients with Barrett's esophagus: the need for long-term subjective and objective follow-up. Ann Surg 2002, 235:178-185.
30. Csendes A, Burdiles P, Braghetto I, et al..: Early and late results of the acid suppression and duodenal diversion operation in patients with Barrett's esophagus: analysis of 210 cases. World J Surg DOI: 10.1007/s00268-001-0269-z.
31. May A, Gossner L, Pech O, et al.: Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett's esophagus (SSBE): curative treatment using local endoscopic treatment techniques. Endoscopy 2002, 34:604-610. Local endoscopic treatment in form of mucosectomy, thermal coagulation or PDT is an attractive alternative to esophageal resection in high-grade dysplasia and early adenocarcinoma.
32. Weston AP, Sharma P: Neodymium:yttrim-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma. Am J Gastroenterol 2002, 97:2998-3006.
33. Kahaleh M, Van Laeathem JL, Nagy N, et al.: Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression. Endoscopy 2002, 34:950-955. Long term follow up results after argon plasma coagulation in patients with Barrett's esophagus. Successful reversal of Barrett's esophagus was related to the length of the segment and high dose acid suppression.
34. Basu KK, Pick B, Bale R, et al.: Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium. Gut 2002, 51:776-780.
35. Sampliner RE, Camargo L, Fass R: Impact of esophageal acid exposure on the endoscopic reversal of Barrett's esophagus. Am J Gastroenterol 2002, 97:270-272.